DiaMedica Therapeutics Inc. (Nasdaq: DMAC) reported third-quarter 2026 financial results on November 12 alongside two significant development milestones for its investigational recombinant human tissue kallikrein-1 therapy, DM199. The biotechnology company has completed enrolment in the first two dose cohorts of its Phase 2 early-onset fetal growth restriction programme and reached the 200-participant threshold required for a planned interim analysis of its ReMEDy2 Phase 2/3 acute ischaemic stroke trial.
The developments place DiaMedica ahead of two distinct clinical evidence events. Preliminary results from the first twelve participants in the fetal growth restriction study are scheduled for discussion on November 24, 2026, while the independent interim analysis of ReMEDy2 is expected in the first quarter of 2027 after the 200th enrolled participant completes 90-day follow-up. Neither milestone represents confirmation that DM199 improves patient outcomes, but both could influence the design, pace and financing requirements of subsequent development.
The financial context is increasingly important. DiaMedica ended September 2026 with $34.9 million in cash, cash equivalents and short-term investments, down from $59.9 million at the end of 2025, as clinical spending increased. Management expects its available resources to support planned operations into the fourth quarter of 2027, leaving a defined period in which the company must generate additional clinical information and make decisions about programme priorities.
Why could the November fetal growth restriction results become an important DM199 development milestone?
DiaMedica’s investigator-sponsored Phase 2 fetal growth restriction study is being conducted at Tygerberg Hospital in Cape Town, South Africa. The investigation is an open-label, single-centre, single-arm proof-of-concept programme designed to assess safety, pharmacodynamic effects and exploratory clinical findings. The first two cohorts enrolled six participants each at DM199 doses of 5 micrograms per kilogram and 10 micrograms per kilogram.
The study focuses on early-onset fetal growth restriction, a condition in which a fetus fails to achieve its expected growth potential, often because of inadequate placental function. Severe cases create difficult clinical decisions because continued pregnancy may increase fetal risk, while early delivery exposes the infant to complications associated with prematurity. A treatment capable of safely improving the underlying maternal or placental vascular environment would therefore address an important clinical need.
DM199 is intended to replace or supplement activity associated with tissue kallikrein-1, an enzyme involved in biological pathways associated with vascular regulation. DiaMedica is investigating whether this mechanism may help address vascular dysfunction implicated in pregnancy-related complications. The biological rationale supports clinical investigation, but it does not establish that the therapy can improve placental blood flow, fetal development or pregnancy outcomes.
The November 24 presentation is expected to provide preliminary safety and clinical information from the first two dose cohorts. Because only twelve participants have been enrolled across these cohorts, the findings will be especially limited in their ability to establish treatment efficacy. Without a concurrent control group, changes in maternal or fetal measurements may also be difficult to distinguish from natural disease variation, clinical management and differences in baseline severity.
The most useful evidence may therefore concern feasibility, tolerability, pharmacodynamic activity and whether the observations justify continued dose exploration. A favourable early signal could strengthen the rationale for further controlled testing, while unexpected safety findings or limited pharmacological activity could affect dose selection and future study design. The announcement provides no numerical fetal growth restriction efficacy results, so any assumption of treatment benefit would be premature.
How could the ReMEDy2 interim analysis change the acute ischaemic stroke programme?
The ReMEDy2 trial is a Phase 2/3 investigation of DM199 in acute ischaemic stroke, registered as NCT05065216. DiaMedica reported that enrolment had reached the prespecified 200-participant threshold for an interim assessment, with the independent Data Safety Monitoring Board expected to conduct the analysis once the relevant 90-day follow-up is complete. Recruitment will continue while the assessment is prepared and undertaken.
The trial’s key efficacy measure concerns the proportion of participants achieving a modified Rankin Scale score of zero or one. The modified Rankin Scale is commonly used to assess disability following stroke, with scores of zero or one representing no symptoms or no significant disability despite symptoms. This endpoint is clinically relevant because it focuses on functional recovery rather than relying exclusively on imaging findings or biological markers.
The interim assessment is designed to evaluate whether the study should continue under its existing assumptions, undergo sample-size re-estimation or stop for futility. DiaMedica disclosed that the final sample size could range from 300 to 728 participants if the trial continues, depending on the predetermined statistical plan. The company is expected to remain blinded to the interim efficacy information, with the independent monitoring board responsible for the assessment.
That structure makes the upcoming analysis consequential even if no detailed efficacy results are publicly released. A recommendation to increase sample size could indicate that more participants are required to answer the trial’s primary question with the planned statistical reliability. Such a recommendation would not automatically mean the investigational medicine has failed, but it could extend the study’s duration and increase development expenditure.
Conversely, continuation without a substantial sample-size change would not establish success. Interim monitoring is intended to preserve trial integrity while addressing statistical and ethical considerations, and the final efficacy conclusion depends on the completed study. A futility recommendation would be more consequential because it could substantially alter the programme’s prospects, although DiaMedica has not reported such an outcome.
The central clinical question is whether DM199 can provide meaningful improvements in functional recovery within the treatment conditions being evaluated. Acute ischaemic stroke outcomes are influenced by baseline severity, treatment timing, reperfusion interventions and other patient characteristics. A credible trial result must demonstrate that any observed benefit is attributable to treatment rather than differences in these factors.
What does DiaMedica’s preeclampsia programme reveal about its regulatory strategy?
DiaMedica is pursuing additional development of DM199 in preeclampsia, a pregnancy complication characterised by elevated blood pressure and associated organ dysfunction. The company has already completed an initial late-onset preeclampsia dose-escalation component involving participants studied shortly after delivery. Management reported that observations from this programme supported the rationale for investigating earlier disease settings.
However, findings obtained after delivery cannot automatically establish safety or therapeutic benefit during an ongoing pregnancy. An investigational medicine administered while the fetus remains in utero requires assessment of maternal effects alongside potential fetal exposure and developmental risks. This creates additional nonclinical, regulatory and ethical requirements compared with studies conducted entirely after delivery.
Health Canada authorised DiaMedica’s planned open-label Phase 2 early-onset preeclampsia study in September 2026. The company intends to enrol approximately 30 participants across three dose levels, using information from its earlier preeclampsia investigation and the fetal growth restriction programme to guide dose selection. DiaMedica is also preparing potential expansion into the United Kingdom, subject to the necessary authorisations.
In October, the company disclosed conditional European trial authorisation, with further country-specific ethical and site requirements remaining. These developments create potential pathways for international clinical recruitment but should not be confused with marketing authorisation for DM199. The programme remains investigational, and the available evidence is insufficient to establish clinical benefit in early-onset preeclampsia.
The United States regulatory pathway has additional unresolved requirements. DiaMedica is responding to United States Food and Drug Administration feedback concerning reproductive toxicity information needed to support an Investigational New Drug application for its preeclampsia programme. Management believes an existing rat reproductive toxicity study may satisfy part of the requirement if additional evidence establishes adequate exposure and pharmacological activity, but the agency has not yet confirmed that conclusion.
The company plans to submit the relevant nonclinical information after the additional analyses are completed. Until the FDA reviews that package and permits the proposed clinical investigation, the United States pathway remains dependent on further regulatory assessment. International trial permissions do not automatically resolve the requirements applicable in another jurisdiction.
How do DiaMedica’s third-quarter financial results affect its clinical development options?
DiaMedica reported a net loss of $11.3 million for the quarter ended September 30, 2026, compared with $8.6 million in the corresponding 2025 period. Research and development expenditure rose to $9.2 million from $6.4 million, reflecting expanded clinical operations, regulatory and reproductive toxicity work, manufacturing development and additional personnel costs. General and administrative expenditure decreased slightly to $2.4 million from $2.6 million.
For the first nine months of 2026, research and development spending reached $25.4 million, compared with $17.9 million in the corresponding prior-year period. Net cash used in operating activities increased to $26.0 million from $21.3 million. These figures show that DiaMedica’s expanding clinical programme is increasing its funding requirements before the company has generated commercial revenue from DM199.
The September 30 cash and short-term investment balance of $34.9 million must therefore be considered alongside future operating commitments and the potential outcome of ReMEDy2’s adaptive interim analysis. Management expects funding to remain available into the fourth quarter of 2027 under its current operating plan. However, a larger stroke trial, additional pregnancy-related studies or extended development timelines could change the rate at which cash is consumed.
This creates an important connection between scientific evidence and financial flexibility. Strong preliminary findings in fetal growth restriction could support further investment or partnership discussions, but would not remove the need for larger clinical studies. Similarly, ReMEDy2 continuation could preserve the stroke programme’s potential while increasing the amount of capital required to reach a definitive result.
A company developing several indications around one investigational molecule can benefit from shared manufacturing, pharmacology and regulatory knowledge. Nevertheless, the programmes have different patient populations, clinical endpoints and safety requirements. Positive findings in one indication would not establish efficacy in the others, so resource allocation must remain sensitive to the strength of each individual evidence package.
What will determine whether DM199 advances beyond its current clinical stage?
DiaMedica’s immediate development calendar contains meaningful but different types of milestones. The November 24 fetal growth restriction presentation will provide preliminary information from a small, uncontrolled investigation, while the ReMEDy2 interim analysis is designed to support decisions about trial continuation and sample size rather than deliver a final efficacy conclusion. The preeclampsia programme must also resolve remaining regulatory requirements and progress into further clinical testing.
For maternal-fetal medicine specialists, the most important questions concern whether DM199 produces measurable effects that could plausibly translate into safer pregnancy prolongation or improved maternal and neonatal outcomes. Those outcomes would ultimately need to be demonstrated through appropriately designed clinical studies. For stroke specialists, the critical question is whether treatment improves the probability of meaningful functional recovery under the conditions assessed in ReMEDy2.
The company’s financial position adds a measurable commercial constraint. DiaMedica currently expects to remain funded into late 2027, but clinical development could require additional resources before regulatory submissions or potential commercialisation. Partnerships, additional financing or programme prioritisation may become relevant depending on the emerging data and revised development plans.
The next several months will therefore be important for determining how DiaMedica allocates capital across DM199’s indications. The strongest outcome would not simply be a collection of encouraging biological observations, but evidence that at least one programme can advance towards a clearly defined, adequately powered clinical test with a manageable financing requirement. The November fetal growth restriction findings and the first-quarter 2027 ReMEDy2 analysis will provide important information for those decisions.
